Canada Life
KRYS icon

Canada Life’s Krystal Biotech KRYS Stock Holding History

Canada Life’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.06M Buy
21,711
+298
+1% +$89K 0.01% 589
2026
Q1 		$5.53M Sell
21,413
-674
-3% -$179K 0.01% 704
2025
Q4 		$5.45M Buy
22,087
+689
+3% +$145K 0.01% 712
2025
Q3 		$3.78M Buy
21,398
+551
+3% +$82.5K 0.01% 947
2025
Q2 		$2.86M Sell
20,847
-3,762
-15% -$553K ﹤0.01% 1036
2025
Q1 		$4.43M Sell
24,609
-2,145
-8% -$361K 0.01% 840
2024
Q4 		$4.19M Sell
26,754
-22
-0.1% -$3.9K 0.01% 928
2024
Q3 		$4.87M Sell
26,776
-597
-2% -$115K 0.01% 880
2024
Q2 		$5.03M Buy
27,373
+24,245
+775% +$4.07M 0.01% 824
2024
Q1 		$557K Buy
3,128
+1,397
+81% +$194K ﹤0.01% 1667
2023
Q4 		$213K Hold
1,731
– – ﹤0.01% 1836
2023
Q3 		$201K Buy
1,731
+1,040
+151% +$127K ﹤0.01% 1858
2023
Q2 		$82K Sell
691
-55
-7% -$5.62K ﹤0.01% 1945
2023
Q1 		$60K Sell
746
-267
-26% -$21K ﹤0.01% 2042
2022
Q4 		$81K Hold
1,013
– – ﹤0.01% 2014
2022
Q3 		$70K Hold
1,013
– – ﹤0.01% 2049
2022
Q2 		$67K Hold
1,013
– – ﹤0.01% 1991
2022
Q1 		$72K Buy
1,013
+346
+52% +$21.6K ﹤0.01% 2080
2021
Q4 		$47K Hold
667
– – ﹤0.01% 2188
2021
Q3 		$35K Hold
667
– – ﹤0.01% 2322
2021
Q2 		$45K Sell
667
-338
-34% -$23.6K ﹤0.01% 2303
2021
Q1 		$77K Buy
1,005
+395
+65% +$28.7K ﹤0.01% 2166
2020
Q4 		$36K Hold
610
– – ﹤0.01% 2392
2020
Q3 		$26K Hold
610
– – ﹤0.01% 2377
2020
Q2 		$25K Hold
610
– – ﹤0.01% 2443
2020
Q1 		$27K Hold
610
– – ﹤0.01% 2310
2019
Q4 		$33K Hold
610
– – ﹤0.01% 2397
2019
Q3 		$21K Sell
610
-1,210
-66% -$54.1K ﹤0.01% 1077
2019
Q2 		$73K Buy
+1,820
New +$59.5K ﹤0.01% 2323

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Canada Life's KRYS Position: Q2 2026 in Review

Canada Life increased its Krystal Biotech (KRYS) stake by 1.4% in Q2 2026, buying an estimated $89K and bringing the position to 21,711 shares worth $8.06M. The position accounts for 0.01% of the portfolio, ranked #589.

Canada Life first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Canada Life held 21,711 shares of Krystal Biotech worth $8.06M as of Q2 2026.
  • Canada Life bought 298 Krystal Biotech shares in Q2 2026, an estimated $89K.
  • Krystal Biotech made up 0.01% of Canada Life's portfolio in Q2 2026, its #589 holding.
  • Canada Life first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.